Skip to main content
Best of #ACR22 Day 2 in PSA

-Efficacy and Safety Results from BE OPTIMAL in PsA
-JAK inhibitors in rheumatic diseases

Dr. John Cush RheumNow

3 years 11 months ago
Best of #ACR22 Day 2 in PSA -Efficacy and Safety Results from BE OPTIMAL in PsA -JAK inhibitors in rheumatic diseases -Who is the Winner? Switch vs Cycle in PsA -Women vs. Men: Response to Treatment in Seronegative Arthritis and more. https://t.co/JSKafxioMT https://t.co/Ov0VuCdX5y
SLE, Sex and STDs

Once in a while, I find an abstract at the American College of Rheumatology meeting that can potenti

Dr. John Cush RheumNow

3 years 11 months ago
SLE, Sex and STDs Once in a while, I find an abstract at the American College of Rheumatology meeting that can potentially save lives and be implemented in practice now. Dr. Dao ( @KDAO2011) discusses abstract #0939 presented at #ACR22. https://t.co/0DtAgzB41G https://t.co/O1z7J0O4c6
TNFi cycling in axSpA: Results from CorEVITAS Registy study

Dr. Rachel Tate ( @uptotate) reviews abstract #1499 presen

Dr. John Cush RheumNow

3 years 11 months ago
TNFi cycling in axSpA: Results from CorEVITAS Registy study Dr. Rachel Tate ( @uptotate) reviews abstract #1499 presented at #ACR22. https://t.co/rvzB2RHkAD https://t.co/m3uiXAvZmZ
The exact role of diet, physical activity, and stress management in the management of RA has long been debated. While reasonable evidence has supported the importance of physical activity in patients with RA, its capacity to reduce disease activity via conventional measures such as DAS28 was less well delineated.
New Treatments for SLE?

Dr. Petri discusses abstract 1117 presented at #ACR22. Efficacy & Safety of Deucravacitini

Dr. John Cush RheumNow

3 years 11 months ago
New Treatments for SLE? Dr. Petri discusses abstract 1117 presented at #ACR22. Efficacy & Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Patients w/Active SLE: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study https://t.co/nKOserLdbb https://t.co/xhVsxT8BZW
RA Topic Panel

RheumNow recaps the best & most interesting data presented at #ACR22 in RA. Panelists: Drs.Conway, N

Dr. John Cush RheumNow

3 years 11 months ago
RA Topic Panel RheumNow recaps the best & most interesting data presented at #ACR22 in RA. Panelists: Drs.Conway, Najm, Liew, Pope, Segan Follow: @RichardPAConway @AurelieRheumo @drdavidliew @Janetbirdope @JulianSegan https://t.co/GMqRmF2yXA https://t.co/WmYRTp49Rv
Proposed Cancer Screening for Inflammatory Myositis Patients

11/12's plenary session features a novel proposal on how

Dr. John Cush RheumNow

3 years 11 months ago
Proposed Cancer Screening for Inflammatory Myositis Patients 11/12's plenary session features a novel proposal on how and which patients with Idiopathic Inflammatory Myopathy (IIM) should be screened for cancer. https://t.co/JlGGZ6UnOc https://t.co/86OnuLINPy
Discussions regarding family planning, contraception, and pregnancy should be approached at each clinic visit to ensure providers understand patients’ personal goals. These conversations have the potential to decrease the risk of unplanned pregnancies. However, rheumatologists may need to manage unplanned pregnancies and the impacts of accidental teratogenic exposure.
Since reduced proteinuria at one year is the best predictor of improved long-term renal outcomes in lupus nephritis, is there rationale to set a tighter treatment target?
×